Merrimack Pharmaceuticals Inc. is a Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer.
Merrimack Pharmaceuticals Inc. (MACK) had a good day on the market for Friday November 27 as shares jumped 1.32% to close at $3.83. About 21,389 shares traded hands on 130 trades for the day, compared with an average daily volume of n/a shares out of a total float of 13.38 million. After opening the trading day at $3.78, shares of Merrimack Pharmaceuticals Inc. stayed within a range of $3.87 to $3.76.
With today’s gains, Merrimack Pharmaceuticals Inc. now has a market cap of $51.25 million. Shares of Merrimack Pharmaceuticals Inc. have been trading within a range of $4.75 and $1.49 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company’s core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Merrimack Pharmaceuticals Inc. is based out of Cambridge, MA and has some 27 employees. Its CEO is Gary L. Crocker.